002737.SZ
葵花药业
SZSE · Healthcare · C 制造业 · CN
CNY 12.86
−1.38%Year over year
Reported trailing growth
- Revenue
- -1.0%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +187.7%
- Operating cash flow
- +234.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -23.1%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -36.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026